@jmaakaron.bsky.social
I read this as CART is feasible in r/r BL and could serve as a bridge to allogeneic transplant given encouraging CR rates but short duration of response.
23.07.2025 09:25 — 👍 1 🔁 0 💬 0 📌 0I said: Revumenib in AML and Dara in SMM. I got an email that I need to expand on these. I said that they weren't there and now they are so I can use them. I get the above email that "ASH Reviewers" denied my CME.
Absolutely bonkers!
#ASH24 #nonsense
@ash-hematology.bsky.social
Thank you #ASH24 for a fun meeting and all the education. Also, thank you for easy CME process:
Step ONE: Pay $30 before anything else. OK
Step TWO: Pick and EVALUATE EACH session you attended. Fine makes sense.
Step THREE: Write a statement
Also, HTN as the reason for being anthracycline ineligible in 80% is fairly arguable.
09.12.2024 23:30 — 👍 1 🔁 0 💬 1 📌 0
#ASH24
#BMTsm
Pierini -
1. Novel conditioning regimens: TMLI
2. Graft manipulation Treg/Tcon or a/b(-)
3. Donor selection: NK cell reactivity and others
#ASH24
Reducing post allo relapse - Vago
Knowledge of mechanism of relapse post allo is important to direct therapeutics
Generic HLA loss
Epigenetic loss of HLA II
Offending drugs and genotoxic/microbiotic
#BMTsm
#ASH24
#CeleBMTies
Dr. Steve Devine needs no introduction. One of the greatest BMT investigators of my time. Now starting and running transformative trials through the @nmdp-org.bsky.social
Dr. Logan's presence on #Bluesky should immediately attract whoever is still on the other platform.
#ASH24
#BestSlideSummaries
#WhatAreWeCallingThese skies? Posts? Blues?
#ASH24
#BMTsm
#CeleBMTies
#BMTmemories
Dr. Mukta Arora spotted at ASH. Seminal contributions to the field of GVHD.
#ASH24
Is it a bird? Is it a new CAR-T? Nope. Just good tacos.
Wish you all lines this long for your presentations!
Is Amer Zidan here?
06.12.2024 19:00 — 👍 0 🔁 0 💬 0 📌 0
#ASH24
Airport registration is a nice touch. No line.
Taxi.. different story. #carpool
Really enjoying Bluesky #bsky as I get ready to go to #ASH24
Feels like the old days with good science and nice people. Looking forward to seeing everyone there!
#BMTsm
MMF is not all good. In fact, might be pretty detrimental for engraftment in high doses (and RFS in some papers).
#ASH24
#BMTsm
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
GLP-2 agonist for treatment of aGVHD. 31 patients, mostly with G 3/4 GVHD. ORR ~50% with durable CRs of ~30%. 11 patients with G5 events - unrelated to study drug. Unmet need for non-immunosuppressive therapies
#ASH24
#BMTsm
